Carbohydrate and Peptide †Based Vaccines: The Way Forward

AbstractExisting treatments and therapies give way supported a huge manikin of disorders and transmittals, a significant example creation antibiotics. nonwithstanding the increasing armorial bearing of multi-resistant bacteria, as thoroughly as increased changes discover in the mechanisms account sufficient for variation in vir enforces, involving accumulation of mutations within the genes that code for antibody- carrying sites (know as antigenic drift), has resulted in these new strains non being interdicted as in effect by those treatments that originally targeted them (Reche, Fernandez-Caldas, Flower, Fridkis-H beli and Hoshino, 2014). The knock-on effect has been that the bacteria or virus is able to spread more than easily, and therapeutic treatments ( practiced after a person contracts a disease), become less effective, unable to plump by boosting the armys own resistant system. As a result, it has been spyd that the vaccinum offers the good of preventing t he anticipation of disease occurrence, using advance action to counteract contagion and chronic illness. Prophylactic, and to a lesser extent therapeutic, vaccinums atomic number 18 the most efficient and efficient alternative to separate treatments and prevention of septic and chronic diseases. They work by causing changes to the T- and B-cells of the adaptive immune system to eliminate or prevent pathogen growth (Plotkin, Orenstein, and Offit, 2013). Going back to the introduction of vaccinums more than cc eld ago, these were initially composed of kil guide pathogens, which although successful, similarly ca utilise unacceptably high levels of obstinate reactions. During the age of investigate that turn over since followed, as with the changes observed with antibiotics and other treatments suitable less effective, the need for safer and more effective vaccines has excessively been ac friendshipd. In addition, an better understanding of antigen presentation and subsequ ent recognition has supported the using of newer vaccine emblems (Flower, 2013). Equally, whilst numerous diseases and infections ar controlled by vaccines, for some, no vaccines nurture been substantial, including streptococci pyogenes, gentle immunodeficiency virus (HIV) and hepatitis C virus (HCV) (Wang and Wal theatre of operations, 2005 Barrett and Stanberry, 2009). Efforts to get new vaccines are discussed in more details, with a focus on peptide-based and loot-based vaccines. Challenges are withal discussed, prima(p) to a summary of the potentiality direction of vaccination and search, which describes a lustrous future.Peptide-based vaccinesAn example of a newer category of vaccine is peptide-based vaccines. Peptides are get around successions of proteins, and diseases/infections use these proteins as part of their flesh out on the immune system. In more cases, the immune system has the ability to recognise the proteins associated with an attack by diseas e or infectious causing pathogens and can respond effectively. just as observed with mevery crab louses, HIV, HCV and other conditions, an effective immune resolution is not triggered, hence the need for newer vaccine increases including those based on peptides, which encompass star proteins or synthetic peptides encompassing umteen antigenic determinants (B- and T-cell epitopes) (Flower, 2013). Peptide vaccines are a instance of subunit vaccine, which presents an antigen to the immune system, using the peptide of the original pathogen, supporting immunity. such(prenominal) peptide-based vaccines avoid the adverse effects described with traditional whole-organism vaccines (Moisa and Kolesanova, 2012) with additional benefits as well as noted (Ben-Yedidia and Arnon, 1997), including The absence of infectious material An immune response that is unique(predicate), focalisation only on the targeted epitope, with the induction of site- circumstantial antibodies No risk of an immune attack or cross-reactivity with the host tissues Flexibility, with an ability to modify products accordingly Improved forcefulness in relation to manufacturing on a large scale, and long-term holding where necessary e.g. a pandemic. However, a turning of difficulties adopt been encountered during the training of such vaccines (Simerska, Moyle and Toth, 2011 Dudek, Perlmutter, Aguilar, Croft and Purcell, 2010) including A short biological activity of peptides due to degradation by enzymes The trigger of a weak immune response when used completely i.e. single peptidesFinding optimal delivery systems.As a result, and to get well the difficulties mentioned above, synthetic peptide vaccines run through been developed, on the basis that a greater more accurately targeted immune response exit be achieved. Peptide antigens are not immunogenic by themselves, so this has led to investigations into co-administration of subunit peptide antigens with adjuvants (immunostimulants) to increase the peptide- pretendd responses to corresponding antigens. eliminate delivery systems and frequently venomous adjuvants have present effective immunity, however, although many adjuvants are described in the literature, only a few have been approved for use with vaccines for delivery in humans due to their perniciousness and include water/oil emulsions, liposomes, and bacterial lipophilic compounds to offer a few examples (Heegaard et. al., 2010). Incomplete Freunds adjuvant (IFA) and Montanide ISA (both oil-based) have been used in clinical trials. Focusing on liposomes as another example, enquiryers have demonstrated that use of lipid core peptide (LCP) technology (lipidation of peptides) remedys the effectiveness of a self-adjuvanting vaccine delivery system, targeting a specific disease and triggering an effective immune response. This system provides a promising platform for human vaccine training (Zhong, Skwarczynski and Toth, 2009 Moyle and Toth, 2008). In an imal models, peptide vaccines have been effective in generating the required immune response, and during new-fangled years, peptide-based vaccines have advanced from animal models and pre-clinical studies, to human clinical trials (Yang et al., 2001). Although currently, all known peptide vaccines under development for humans remain at the stage of clinical trials, these trials should build on the promising evidence resulting from query to date of the potential drill of vaccine candidates based on a LCP system, as well as other strategies. Prevention of not only many infectious diseases including hepatitis C virus, malaria, human immunodeficiency virus and radical A streptococci), merely also for pubic louse immunotherapy and improved allergen specific tolerance, remains an exciting, and very real possibility.Carbohydrate-based vaccinesThe development of vaccines based on carbohydrates not only has quite a history, solely is also an area that is fast moving in the current qu ery world. The literature provides evidence as far back as the previous(predicate) 1900s where researchers discovered a connection mingled with cause-specific polysaccharides and the induction of antibodies being developed against certain types of pneumococci (Francis and Tillett, 1930). This was confirmed by evidence of pneumococcal capsular polysaccharides being used as vaccines, providing effective and long lasting immunity (Heidelberger, Dilapi, Siegel and Walter, 1950). However despite these early findings, the discovery and success of other treatments such as antibiotics and chemotherapeutics led to this area of research being put on hold. As mentioned earlier however, due to increased resistance to existing treatments such as antibiotics, coupled with the recognition for a need of newer treatments including improved vaccines, renewed quest into preventive vaccines has resulted in novel approaches, which include carbohydrate vaccines. vaccines are ordinarily made from we akened pathogens, or, as we now know, other approaches also use immunogenic proteins or polysaccharides. Carbohydrates have been the centre of attention in the research country of vaccination because not only do they exhibit more stability than proteins, but they have roles in both physiology and pathophysiology, including cell interaction and signalling, inflammation, pathogen host adhesion/recognition, to name a few examples (Doshi, Shanbhag, Aggarwal, Shahare and Martis, 2011). During the last ten years or so, they have been used as adjuvants, as newsboys for protein antigens to aid immunotherapy, and as targets for vaccines against bacteria. Additionally, as observed with DNA and proteins, carbohydrates are now recognized as biopolymers also, playing a role in many molecular and biological activities (Doshi et. al., 2011). These discoveries, partnered by an improved understanding of the immune system and the identification of specific and relevant carbohydrate structures, l ed to the development of glyco immixs, which in turn led to carbohydrate vaccine development (Holemann and Seeberger, 2004). Glycoconjugates are present in the surfaces of cells, as well as in the surrounding extracellular matrices and connective tissue. thence both the identified structure and presence of glyconjugates, plus the role they play, convey they are a suitable basis for the development of new vaccines. introduction of protective antibodies is key to an effective immune response as a result of a vaccine, and as with peptide vaccines, challenges have been evident in the research to develop effective carbohydrate vaccines, including the following Glycans struggle to effectively induce protective antibodies Carbohydrates have a low immunogenic impact by themselves (as observed with peptides). There are two main carbohydrate vaccine types 1. lifelike carbohydrate vaccines these include small amounts of impurities 2. unreal carbohydrate vaccines these are produced with no contaminants, and are cost-effective due large-scale production. Synthetic carbohydrate antigens used to develop vaccines have triggered immune responses in clinical studies and are gold given the risk of adverse effects with natural vaccines. Four all important(p) aspects need to be considered for the design of carbohydrate-based vaccines (Astronomo and Burton, 2010) The antigen source glycan antigens are diverse, ranging from large polysaccharide capsules, to small monosaccharides, to oligosaccharides, all of which have been shown to be adequate for preparation of vaccines. The immune carrier this is most often proteins, although other materials have been investigated, with the aim of ensuring that the link between the antigen and the carrier is specific. The rule of conjugation (or ligation) protein conjugates, lipid conjugates and polyvalent scaffold conjugates have been developed. The success of a conjugate vaccine depends partly on the method of conjugation employed. This should be simple and efficient, as well as causing minimal distortion to the individual components involved, with many differing techniques used (Zou & Jennings, 2009 Ada and Isaacs, 2003). The pick of adjuvant required to improve immunogenicity of the carbohydrate antigens being targeted, with a contain choice approved for use in humans.Examples of diseases targeted by carbohydrate-based vaccines The discussion will now move on to the use of carbohydrate-based vaccines in three disease areas Group A Streptococcus ( mess up), HIV/ assist and Haemophilus flu type b. fluid The need for a safe, effective, affordable and practical vaccine against GAS (also known as Streptococcus pyogenes), has been recognised for many years, as has the research into a vaccine against this disease, given the global burden on wellness that this disease causes in particular(prenominal) in less developed countries. more(prenominal) than 500,000 deaths result from the GAS each year, with the bacteria causing a cut back of both less complicated and life-threatening illnesses (Carapetis, Steer, Mulholland and Weber, 2005). The diversity of GAS strains is the study challenge for the development of an anti-GAS vaccine, with more than 100 different strains identified, of which the genetic sequence for several different strains have been determined (Johnson and Pinto, 2002). reticuloendothelial systemearch has identified that GAS bacteria contain a surface polysaccharide made up of long, repetitive polysaccharide chains. The conserved and constant arrangement of these chains suggests conjugate vaccines to be an attractive and achievable option, with animal models supporting this theory (Cunningham, 2000). Synthetic carbohydrate vaccines, although only studied in a limited hard-boiled of GAS infections, have demonstrated a protective immune response (Robbins et al., 2009). In addition, some areas of research have focused on the molecular analysis of a surface protein labelled the M protein, which is encoded by the emm gene. This particular gene has been found to be the major cause of GAS associate clinical manifestations (Smeesters, McMillan and Sriprakash, 2010). These findings have allowed a greater understanding of the functioning of specific proteins responsible for the virulence of the disease, which in turn, supports the development of potential GAS vaccines. vaccinum prevention of GAS and the resulting symptoms and complications has been a goal of researchers for many years. A number of vaccines have been in research development to offer tribute against GAS, with the research vaccine strategies focusing on either M protein, or non-M protein antigens (Smeesters, 2014). However only those vaccines that use the M protein as the antigen have progressed to clinical trials (McNeil et. al., 2005), and have included conserved antigens coverage across the many strains of GAS, a type-specific vaccine based on the N-terminal portion of the M protein, and a reco mbinant vaccine that reached shape II clinical trials (Pandey, Wykes, Hartas, Good and Batzloff, 2013 Bauer, 2012). However no vaccine has currently reached licensing and so the diseases caused remain uncontrolled in many areas, with reviews covering the research suggesting that even those vaccines developed with the aim of providing large coverage of GAS strains, these vaccine might achieve acceptable coverage in developed countries, but in less developed countries where the disease burden is much greater, the arbitrary impact of the vaccines would be much lower due to a greater strain diversity (Smeesters, McMillan, Sriprakash, and Georgousakis, 2009 Steer, Law, Matatolu, Beall and Carapetis, 2009 McMillan and Sanderson, 2013). Equally, antibiotic treatment is either impractical with regards to implementation (specifically in less developed countries) or ineffective. 1 research group targeted the bacteria by synthesising a new self-adjuvanting vaccine candidate, incorporating a carbohydrate carrier and an amino acid-based adjuvant, resulting in successful synthesis and characterisation of the vaccine candidate. This may contribute to the identification of a safe and effective vaccine against GAS in the future (Simerska et. al., 2008 Simerska, Lu and Toth, 2009). HIV/AIDS One of the main challenges researchers have faced within the field of vaccine development against HIV/AIDS, is that the virus surface is covered with layers of glycans, which conceal underlying viral antigens that are potential good targets in the production of vaccines (Scanlan, Offer, Zitzmann, and Dwek, 2007). They are produced by the host cell, which makes the virus appear as self resulting in no attack being triggered by the host immune system. The layers of carbohydrate also contain mannose residues, making these another potential target for a vaccine aimed at preventing HIV infection, whereby lectins preferentially bind to ? 1-2 linked mannose residues. Such lectins are being inve stigated as workable therapeutic tools (Tsai et al., 2004) although the fact that lectins are often toxic needs to be researched further to avoid the host immune system damaging host cells. Indeed, other drugs that are known to inhibit synthesis of carbohydrates only have this effect at often toxic concentrations to cause antiviral activity. Another strategy based on the uniform principle of developing a carbohydrate vaccine, is the identification of antibodies that again recognise and bind to glycans. (Scanlan et al., 2002, Scanlan et al., 2007). The antibody appears to recognize these glycans because although they belong to the host, they are arranged in a non-self manner (Scanlan et al., 2002 Scanlan et al., 2007), making the production of effective ant-HIV vaccines a real possibility, in addition to vaccines for other diseases such as cancer (Galonic and Gin, 2007). Studies have also been described using immune enhancing adjuvants, carrier peptides such as keyhole limpet hemoc yanin and change glycan structure constructs that support immune recognition in the development of vaccines against cancer (Galonic and Gin, 2007). These same strategies are being used in development of possible HIV vaccines, where antibodies target self-carbohydrates arranged slightly differently on cancer cells and HIV-infected cells, in comparison to wholesome cells. (Galonic and Gin, 2007). These approaches have not as stock-still led to clinically effective vaccines, but it is clear that antibodies that strongly bind to carbohydrate antigens on, for example, prostate cancer cells, have been generated (Slovin et al., 2003) and this appears to be a highly promising approach. Further exploration is required based on the carbohydrate coat of the virus, which may lead to improved prevention treatment of HIV. Haemophilus influenza type bThe first synthetic vaccine for human application was developed in 2003 for protection against Haemophilus influenza type b vaccine, not only prov iding protection against this bacteria, but also against all the associated diseases it causes ranging from meningitis, septicaemia, pneumonia and arthritis (Doshi, Shanbhag, Aggarwal, Shahare and Martis, 2011). Indeed this bacterium is the leading cause of serious illnesses in children under 5 years worldwide. The majority of strains of Haemophilus influenza are non-encapsulated, and are lacking in any carbohydrate polysaccharide protective structure, as opposed to the GAS bacteria and HIV virus described earlier. This structural information armed researchers with the knowledge that carbohydrate polysaccharide conjugate vaccines would be required to ensure the development of an effective vaccine (Verez-Bencomo et. al., 2004). As a result, carbohydrate-based vaccines have been licensed for protection in humans against haemophilus influenza type b, using oligomerization and a carrier protein (Doshi et. al., 2011).Evidence of progressTo end this section of the discussion, several conj ugate polysaccharide carbohydrate vaccines are now well into pre-clinical/clinical development, or have been licensed and are now commercially available. Examples of licensed vaccines include the following (Astronomo and Burton, 2010) Haemophilus influenza type b (Hib) 4 carbohydrate-based vaccines are licensed via 3 different pharmaceutic companies ActHIB and Hiberix Pentacel PedvaxHIB and Comvax Neisseria meningitides A, C, Y and W-135 2 carbohydrate-based vaccines are licensed via the same pharmaceutic play along Menactra and Menomune-A/C/Y/W-135 Salmonella typhi 1 carbohydrate- based vaccine is licensed TYPHIM Vi Streptococcus pneumonia variants 2 carbohydrate-based vaccines are licensed via 2 different pharmaceutical companies Prevnar and Pneumovax 23.Examples of carbohydrate-based vaccines in development include the following, where the disease is described in addition to the stage of development (Astronomo and Burton, 2010) Breast cancer with 1 vaccine at the preclinica l phase and a second at phase I Prostate cancer 4 vaccines are in development at the preclinical, phase I and phase II stages HIV-1 1 vaccine at the preclinical phase Group A strep 1 vaccine at the preclinical phase Group B streptococcus 1 vaccine at phase II.ConclusionIt is fact that vaccines have had a major role to play in the success of preventing and treating many diseases, however many challenges remain. sicknesss exist for which no effective vaccines have yet been discovered, including HIV/AIDs. In addition, diseases that have been controlled by vaccines in some part of the world continue to affect the lives of people adversely in other areas where infrastructures for vaccination are poor/non-existent. Continued research is necessary to develop vaccines not only for those diseases with no vaccine available, but also to improve the effectiveness of existing vaccines. In addition to research focusing on novel and promising approaches such as carbohydrate and peptide base d vaccines, efforts also need to concentrate on areas such as lower cost, more convenient delivery of vaccines, and longer-term protection. The future direction of research in this field has become focused with the help of new evidence-based information and promising data. The sexual climax of synthetic peptide-based and carbohydrate-based vaccines signified a new era for vaccines, over-taking traditional treatments and vaccines which have become either ineffective or only offer short term protection. As the discussion demonstrates, a number of vaccines are already successfully protecting humans against some pathogens and disease, with the potential for further vaccines to follow. Finally, and by chance most importantly, it should be remembered that unlike drug-based medicines, vaccines primarily offer a cure, a goal all aim to achieve. Word count 3130 (excluding references)ReferencesAda, G. & Isaacs, D. (2003). Carbohydrate-protein conjugate vaccines. clinical Microbiology and In fection. 9(2) p. 79-85.Astronomo, R.D. & Burton, D.R. (2010). Carbohydrate vaccines developing sweet solutions to sticky situations nature Reviews Drug Discovery. 9 p. 30-324.Barrett, A.D.T. & Stanberry, L.R. (Eds.). (2009). Vaccines for biodefence and Emerging and Neglected Diseases. Elsevier Inc., ISBN 978-0-3-69408-9.Bauer M.J., Georgousakis M.M., Vu T., Henningham A., Hofmann A., Rettel M., Hafner L.M., Sriprakash K.S. & McMillan D.J. (2012). Evaluation of novel streptococcus pyogenes vaccine candidates incorporating multiplex conserved sequences from the C-repeat region of the M-protein. Vaccine. 30(12) p. 2197-2205.Ben-Yedidia, T. & Arnon, R. (1997). Design of Peptide and Polypeptide Vaccines. Curr. Opin. Biotech. 8(4) p. 442-448).Carapetis, J.R., Steer, A.C., Mulholland E.K. & Weber, M. (2005). The global burden of group A streptococcal diseases. Lancet Infect Dis. 5(11) p. 685-694.Cunningham M. (2000). Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 1 3 p. 470-511.Doshi, G.M., Shanbhag, P.P., Aggarwal, G.V., Shahare, M.D. & Martis, E.A. Carbohydrate Vaccines- A burgeoning field of Glycomics. ledger of Applied Pharmaceutical perception 1(02) p. 17-22.Dudek, N.L., Perlmutter, P., Aguilar, M.I., Croft, N.P. & Purcell, A.W. (2010). Epitope discovery and their use in peptide based vaccines. Curr Pharm Des. 16 p. 3149-3157.Flower, D.R. (2013). Designing immunogenic peptides. Nature Chemical Biology. 9(12) p. 749753.Francis Jr, T. & Tillett, W.S. (1930). Cutaneous reactions in pneumonia. The development of antibodies following the intradermal scene of type-specific polysaccharide. J. Exp. Med. 52 p. 573585.Galonic, D.P. & Gin, D.Y. (2007). Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines. Nature. 446 p. 10007.Heegaard, P.M.H., Dedieu, L., Johnson, N., Le Potier, M-F., Mockey, M., Mutinelli, F., Vahlenkamp, T., Vascellari, M. & Sorensen, N.S. (2010). Adjuvants and delivery systems in veterinary vaccinology current state and future developments. foul Virol. 156(2)p. 183-202.Heidelberger, M., Dilapi, M.M, Siegel, & Walter, A.W. (1950). Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J. Immunol. 65l pp. 535541.Holemann, A. & Seeberger, P. (2004). Carbohydrate diversity synthetic thinking of glycoconjugates and complex carbohydrates. Curr Opin In Biotech. 15(1) p. 615-622.Johnson, M.A. & Pinto, B.M. (2002). Saturation transfer difference 1D-TOCSY experiments to map the topography of oligosacchraides recognised by a monoclonal antibody directed against the cell-wall polysaccharide group A streptococcus. J Am Chem Soc. 124 p. 15368-15374.McMillan, D.J., Sanderson-Smith, M.L., Smeesters, P.R. & Sriprakash, K.S. (2013). Molecular markers for the study of streptococcal epidemiology. Current topics in microbiology and immunology. 368 p. 29-48.McNeil, S.A., Halperin, S.A., Langley, J.M., Smith, B., Warren, A., Sharratt, G.P., Baxendale, D.M., Reddish, M. A., Hu, M.C., Stroop, S.D., Linden, J., Fries, L.F., Vink, P.E. & Dale, J.B. (2005). Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis. 41(8) p. 1114-22.Moisa, A.A. & Kolesanova, E.F. (2012). Synthetic Peptide Vaccines, Insight and Control of Infectious Disease in Global Scenario. Dr. Roy Priti (Ed.), ISBN 978-953-51-0319-6.Moyle, P.M. & Toth, I. (2008). Self-adjuvanting lipopeptide vaccines. Current Medicinal Chemistry. 15 p. 506516.Pandey, M., Wykes, M.N., Hartas, J., Good, M.F. & Batzloff M.R. (2013). Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help. Journal of immunology. 190(6) p. 2692-701.Plotkin, S.A., Orenstein, W.A. & Offit, P,A. Eds (2013). Vaccines. sixth ed. Edinburgh Elsevier/Saunders.Reche, P.A., Fernandez-Caldas, E., Flower, D.R., Fridkis-Hareli, M. & Hoshino, Y. (2014). Peptide-Based Immunoth erapeutics and Vaccines. Journal of Immunology Research. Editorial. 2014 2 pages.Robbins, J.B., Kubler-Kielb, E., Vinogradov, E., Mocca, C., Pozsgay, V., Shiloach, J. & Scheerson, R. (2009). Synthesis, characterisation, and immunogenicity in mice of Shigella sonnei O-specific, oligosaccharide-core-protein conjugates. Proc Natl Acad Sci USA. 106 p. 7974-7978.Scanlan, C.N., Pantophlet, R., Wormald, M.R., Ollmann Saphire, E., Stanfield, R., Wilson, I.A., Katinger, H., Dwek, R.A., Rudd, P.M. & Burton, D.R. (2002). The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha12 mannose residues on the outer face of gp120. J Virol. 76 p. 730621.Scanlan, C.N., Offer, J., Zitzmann, N. & Dwek, RA. (2007). Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature. 446 p. 103845.Simerska, P.,Abdel-Aal, A.B.M, Fujita, Y., Batzloff, Good, M.F. & Toth, I. (2008). Synthesis and in vivo studies of carbohydrate-based vaccines against group A Streptococcus. Peptide Science. 90(5) p. 611-616.Simerska, P., Lu, H. & Toth, I. (2009). Synthesis of a Streptococcus pyogenes vaccine candidate based on the M protein PL1 epitope. Bioorganic & Medicinal Chemistry Letters. 19(3) p. 821-824.Simerska, P., Moyle, P.M. & Toth, I. (2011). Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products. Med Res Rev. 31 p. 520-47.Slovin, S.F., Ragupathi, G., Musselli, C., Olkiewic,z K., Verbel,D., Kuduk, S.D., Schwarz, J.B., Sames, D., Danishefsky, S., Livingston, P.O. & Scher, H.I. (2003). Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 21p. 42928.Smeesters, P.R., McMillan, D.J. and Sriprakash, K.S. (2010). The streptococcal M protein a highly versatile molecule. Trends Microbiol. 18 p. 275-282.Smeesters, P.R., McMillan, D.J., Sriprakash, K.S. & Georgousakis, M.M. (2009). Differences among group A streptococcus epidemiological landscapes consequences for M protein-based vaccinesExpert Rev Vaccines. 8(12) p. 1705-20.Smeesters, P.R. (2014). Immunity and vaccine development against Streptococcus pyogenes is emm-typing enoughProc Belgian Roy Acad Med. 3 p. 89-98.Steer, A.C., Batzloff, M.R., Mulholland, K. & Carapetis, J.R. (2009). Group A streptococcal vaccines facts versus fantasy. Current judgement in Infectious Diseases. 22(6) p. 544-552.Steer, A.C., Law, I., Matatolu, L., Beall, B.W. & Carapetis, J.R. (2009). Global emm type distribution of group A streptococci systematic review and implications for vaccine development. Lancet Infect Dis. 9(10) p. 611-6.Tsai, C.C., Emau, P., Jiang, Y., Agy, M.B., Shattock, R.J., Schmidt, A., Morton, W.R., Gustafson, K.R., Boyd & M.R. (2004). Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res boil Retroviruses. 20(1) p. 1118.Verez-Bencomo, V., Fernandez-Sa ntana, V., Hardy, E., Toledo, M.E., Rodriguez, M.C., Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo, M., Villar, A., Valdes, Y., Cosme, K., Deler, M.L., Montane, M., Garcia, E., Ramos, A., Aguilar, A., Medina, E., Torano, G., Sosa, I., Hernandez, I., Martinez, R., Muzachio, A., Carmenates, A., Costa, L., Cardoso, F., Campa, C., Diaz, M. & Roy, R. (2004). A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science. 305(5683) p. 552-555.Wang, C.Y. & Walfield, A.M. (2005). Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine. 23(17-18) p. 20492056.Yang, D., Holt, G.E., Rudolf, M.P., Velders, M.P., Brandt, R.M.P., Kwon, E.D. & Kast, W.M. (2001). Peptide Vaccines. In New Vaccine Technologies. Chapter 12 p. 214-226.Zhong, W., Skwarczynski, M. & Toth, I. (2009) Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery. Australian Journal of Chemistry. 62 p. 956967.Zou, W.. & Jennings, H.J. (2009). Preparation of glycoconjugate vaccines. In Carbohydrate-Based Vaccines and Immunotherapies. Chapter 2.